People with weight-related health issues may find these medications helpful, but the potential national influence on obesity is uncertain.
A Pew Research Center survey examines Americans' perceptions on Ozempic and Wegovy, a new weight-control drug class.Weight-loss drugsHow weight-loss drugs affect American obesity. Willpower and weight concerns.
Ozempic, Wegovy, and other weight-loss medicines are familiar to three-quarters of Americans. 53% of individuals familiar with these drugs think they are good weight-loss options for those with obesity or a weight-related health condition, 19% disagree, and 28% are unsure.
Only 12% of those familiar with these drugs advocate them for weight loss without weight-related health concerns. Most (62%) think these drugs are useless for non-obese people, while 26% are undecided.
Drugs like Ozempic have changed obesity treatment and knowledge in America.US citizens deem Ozempic and Wegovy's obesity impact negligible. Only 16% of people familiar with these treatments think they will considerably reduce U.S. obesity, 35% think they will, and 33% expect nothing.
The rise of Ozempic and other related medications has sparked a national debate about weight and its causes, including behavior, environment, and heredity.
Americans consider nutrition the most essential weight factor: Most (57%) or (29%), agree diet affects weight. Second, 43% think exercise affects weight considerably and 36% say it does.
Different American populations and traits agree on weight. Extremely or slightly overweight adults believe stress and worry affect their weight more than healthy adults (40% vs. 29%).
Women say stress and worry affect weight as much as exercise (42% vs. 40%). Hispanic and black women emphasize stress and anxiety's weight impacts.Men prioritize weight-related exercise over stress and concern (46% vs. 29%).
Follow for more updates